alt
alt
  • Home
Illustration of Lymphoseek in action.

Target Ability

Discover LYMPHOSEEK®, the only agent designed and FDA-approved for lymphatic mapping in patients with solid tumors for which this procedure is a component of intraoperative management; guiding sentinel lymph node biopsy in patients with breast cancer, melanoma, and squamous cell carcinoma of the oral cavity; and use with scintigraphic imaging.

Click to watch LYMPHOSEEK in action
 

Why LYMPHOSEEK?

In October 2014, the FDA approved the expanded use of LYMPHOSEEK as a lymphatic mapping agent for solid tumors where it is a component of the intraoperative procedure.

Learn more
 

Designed to identify

LYMPHOSEEK allows for timely and precise identification of tumor-draining lymph nodes.2,3

Learn more
 

Hear from peers

Join one of our upcoming webinars to hear from peers about advances in lymphatic mapping and sentinel lymph node biopsy with LYMPHOSEEK. You will hear about patient case studies and learn results from clinical trials as well as have the opportunity to ask our presenters questions about their clinical experience with LYMPHOSEEK.

Register now
 

30-day trial results

In a 30-day trial of LYMPHOSEEK, Mercy Medical Center observed short procedure times and low pain scores while adding new surgical cases. 

Learn more
 
 
References:  1. LYMPHOSEEK Injection [prescribing information]. Dublin, OH: Cardinal Health; June 2019. 2. Sondak V, King DW, Zager JS, et al. Combined analysis of Phase III trials evaluating Tc99m tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma. Ann Surg Oncol  2013;20:680-8. 3. Wallace AM, Han LK, Povoski SP, et al. Comparative evaluation of [99mTc] tilmanocept for sentinel lymph node mapping in breast cancer patients: results of two Phase 3 trials. Ann Surg Oncol.  2013;20:2590-9.)